INTRODUCTION
The discovery of vaccination by Jenner, as well as the development of the principle of vaccines by Pasteur, had an enormous impact on the eradication of many infectious diseases. These developments opened the road to the development of attenuated (i.e., live) or inactivated (i.e., noninfectious) vaccines; however, such vaccines are not without problems and can have detrimental effects. Indeed, attenuated vaccines can revert to a more virulent form, and inactivated vaccines may produce serious side effects. There also are several infectious diseases for which no vaccines are available. For example, many parasitic infections cannot be prevented by vaccination. These facts, together with recent developments in the fields of molecular and cellular biology, have led to the creation of a new generation of vaccines (73) : recombinant-DNA vaccines, synthetic-peptide vaccines (63) , and idiotypic vaccines (3, 13, 46) . In this paper, I review the principle of idiotypic vaccines, the experimental systems in which they have been used, and their potential advantages over other vaccines.
THE PRINCIPLE OF IDIOTYPIC VACCINES Jerne has described the immune system as a web of interacting variable-region domains, i.e., the idiotypic network (30) . He considers the network to be a logical necessity resulting from the dual character of the antibody molecule, which recognizes an antigen through its antigen-binding site and also is immunogenic by virtue of its idiotypic determinants (38, 48) . In Jerne's description of the network, the antigen-binding site is called the paratope and the antigenic structure associated with the variable region is called the idiotype. An idiotype is public or cross-reactive (IdX) when it is detected in the sera of all individuals responding to a well-defined antigenic challenge. If it is only detected in the serum of one or a few individuals, the idiotype is defined as private (IdI) . Each idiotype is composed of a set of distinct antigenic structures called idiotopes. The T-cell receptor is likewise dual in character; it can bind antigen in a major histocompatibility complex (MHC)-restricted fashion, and anticlonotypic antibody can be raised against antigenic determinants present in the variable portion of the oa,, heterodimer constituting the T-cell receptor (29) . According to Jerne's picture of the network, antigen-binding antibody and anti-idiotypic antibody belong to the same family. This implies that each antibody molecule can bind both an epitope on an antigenic molecule and an idiotope. The latter appears as the internal image of the foreign epitope. Nisonoff and Lamoyi (46) have proposed that such internal-image determinants could be used as vaccines for infectious diseases. This proposal is based on the idea that such determinants can substitute for antigenic determinants displayed on infectious organisms.
If we accept the view that idiotypic interactions play a role in the regulation of the immune response to infectious agents, various types of idiotypic manipulations (the injection of internal-image-bearing antibody being one of them) could influence ongoing regulatory processes. On the basis of the idiotypic-network hypothesis, the idiotypic cascade presented in Fig. 1 can be developed. Figure 1 follows Jerne's original assumption that paratopes and idiotopes are distinct functional entitites. This allows us to deduce which interactions can potentially occur within the idiotypic cascade. For the sake of simplicity, I only present some of the members of the cascade and consider one or two idiotopes associated with the variable region. According to this cascade, the antigenic epitope elicits an immune response, resulting in the production of Ab1 antibody. Ab1 antibody can, in turn, trigger an anti-idiotypic response consisting of distinct subsets of Ab2 antibodies (4, 31) . Ab2a recognizes framework-associated idiotypes (i.e., Ab2a cannot interfere with the binding of antigen by Abl), Ab2-y recognizes idiotopic determinants closely associated with the paratope (i.e., Ab2y inhibits the binding of the antigen to Abl), and Ab2P bears an idiotope mimicking the antigenic epitope (i.e., it is an internal-image Ab2). Ab2a and Ab2-y are induced because their paratopes recognize idiotopes expressed by Ab1. By contrast, Ab2I3 antibodies represent a unique subset of Ab2 because their induction results from the fact that they bear an idiotope complementary to the paratope of Ab1. Therefore, immunization with Ab1 does not always elicit the Ab2P subset. Ab2 antibodies belonging to the different subsets can elicit an anti-anti-idiotypic (Ab3) antibody response. The Ab3 response can be extremely complex, especially if it is elicited against a polyclonal Ab2 consisting of the various subsets, e.g., Ab2cx, Ab2I3, and Ab2Y (Fig. 1) . If a monoclonal antibody belonging to one of those subsets is used, the nature of the Ab3 response will be determined by the nature of this Ab2. Each type of Ab2 is potentially able to induce Ab1-like antibody, because Ab1 bears the internal image of the antigen recognized by Ab2a and Ab2_y (in this case, the internal image is the immunogen itself), whereas Ab2P (69) . In the antigenic systems used in their studies (RNase and Micrococcus lysodeicticus), it seems that the polyclonal Ab2 did not contain significant amounts of Ab2p, because they did not detect Ab1-like antibody in their Ab3. Nevertheless, they showed that animals producing Ab3 were primed for a response to the original antigen, to which they had never before been exposed.
The first demonstration of the existence of an Ab2P came from the work of Sege and Peterson (61) . They showed that anti-idiotypic antibodies prepared against bovine anti-insulin mimics the action of insulin, in that they are able to interact with insulin receptors on tissues and to stimulate the physiological action of insulin itself. Since then, several investigators have produced anti-idiotypic antibodies against antiligand antibodies, which are able to bind the receptor of the corresponding ligand (for a review, see reference 21); how- In two instances, the immunodominant peptidic structure of the antigen has been found in the primary amino acid sequence of the Ab2P. Using the GAT antigen, a (Glu60 Ala30Tyr10). copolymer, Ollier et al. (47) have shown that the DH segment of the heavy chain of a monoclonal Ab2P EXPERIMENTAL MODELS OF IDIOTYPIC VACCINES Several experimental models involving viral, parasitic, or bacterial infections have been developed to examine the basis of the regulatory properties of the idiotypic cascade. Table 1 gives an overview of most systems studied so far.
The first application of idiotypic manipulation for infectious diseases was developed by Sacks and co-workers (57) for Trypanosoma brucei rhodesiense, the causative agent of African sleeping sickness. They produced murine polyclonal anti-idiotypic antibodies against protective murine monoclonal antibody. One of the Ab2 antibodies was able to induce protective immunity when given to allotype-matched mice without adjuvant (59) . This particular anti-idiotypic antiserum contained a large fraction of Ab2-y and an undetectable amount of Ab2, which might explain the ineffectiveness of such treatment in non-allotype-matched mice which do not express this idiotype after parasite infection. Nevertheless, it can be argued that this idiotype is part of the silent repertoire of those mice and could be activated by suitable treatment (i.e., the use of adjuvant or the coupling of the Ab2 to a carrier). The induction of an allotype-restricted idiotype in mice expressing the wrong allotype (i.e., in mice expressing an allotype which is not associated with the expression of this idiotype) has been observed with suitably manipulated animals (44, 49) ; these restricted idiotypes were found to be part of the silent repertoire of the nonexpressor strains. In another case, a rabbit idiotype has been induced in mice not normally expressing that idiotype (19) . In the course of the activation of a silent clone, the treatment with Ab2 primes the animals, and Ab1-like antibodies are usually detected after antigenic challenge.
More recently, with the Trypanosoma cruzi system, Sacks In the reovirus type 3 system, the reovirus hemagglutinin (HA) directs tissue binding and cell tropism and is the major target for the cellular and humoral anti-reovirus type 3 immune responses. An anti-idiotypic monoclonal antibody raised against an anti-reovirus type 3 monoclonal antibody bearing the IdX of the anti-HA response appears to be an Ab2g by several criteria: it binds to the receptor of the virus on target cells (the receptor has been characterized, thanks to the production of a rabbit polyclonal Ab2I [8] ) and mimics its biological activity; it prevents the infectivity of reovirus particles and their binding to target cells (12) ; it triggers an Ab1-like immune response in various species (22) ; and it can trigger T-cell immunity to reovirus type 3 in naive mice (62) . As mentioned in the previous section, there is homology between part of the primary amino acid sequence of the reovirus HA and part of the Ab2P light chain (5).
The fact that the Ab2P of the reovirus system can elicit both B-cell and T-cell immunity is particularly exciting from the immunological point of view. It indicates not only that this Ab2P mimics the three-dimensional structure of HA, as indicated by its ability to bind to the HA receptor, but also that it can even mimic the immunological functions of HA. T-cell activation is usually MHC restricted and requires the processing of high-molecular-weight stimulating antigen. Tcell activation by an Ab2I3 can either result from its processing and MHC-restricted presentation or be a consequence of receptor cross-linking, if the Ab2p behaves as an anticlonotypic antibody. In the reovirus system, the fact that optimal cytotoxic-T-lymphocyte activation was obtained by injecting irradiated B-cell hybridomas, displaying class I and class II MHC molecules as well as the Ab2I3 on their surface, argues in favor of the first hypothesis (62) . Recent studies using Mycobacterium tuberculosis provide clear-cut data on the activation of T-cells by Ab2P. Indeed, it was shown that a monoclonal Ab2f3 raised against a monoclonal Ab1 recognizing a protein antigen can stimulate T-cell proliferation (54) . This stimulation requires the processing of the Ab2f3 and is MHC restricted (55) .
In two other viral systems (poliovirus type II and rabies virus), Ab2 immunization led to the production of virusneutralizing antibodies but did not confer protective immunity (52, 71); however, different immunization schedules, as well as the use of other doses of antigen with or without adjuvant, might yield different results.
In the Sendai virus system, a monoclonal anticlonotypic antibody recognizing the T-cell receptor of a virus-specific T-helper cell clone was used for the first time (15, 16) . Immunization with this anticlonotypic antibody induces protective immunity against Sendai virus infection by eliciting T-cell and B-cell immunity (18) . Interestingly, from the point of view of vaccine development, the T cells induced by the virus are MHC restricted, whereas the T cells activated by the anticlonotype do not express MHC restriction (15, 16) . A similar approach has been developed to induce protective immunity against the intracellular bacterium Listeria monocytogenes (32) . Here, a syngeneic murine polyclonal anticlonotypic antibody was raised against the receptor of a T-cell hybridoma recognizing a protective antigen of L. monocytogenes. Immunization of syngeneic or allogeneic mice with the anticlonotype induced protective immunity.
Another area of interest for the development of idiotypic vaccines is bacterial infections. The immune response to bacterial antigens presents an ontogenic delay, and the vaccination of children with classical vaccines is not very effective (for a review, see reference 64) . Obviously, the use of synthetic-peptide or recombinant-DNA vaccines are of no advantage with respect to antipolysaccharide responses. In fact, in some of the early work on the role of the idiotypic cascade, bacterial antigens were used. Urbain et al. (69) showed that it is possible to prime rabbits to respond to M. lysodeicticus by immunization with Ab2 antibody. Earlier, Eichmann and Rajewsky (14) had found that the injection of an immunoglobulin GI guinea pig Ab2 could enhance the immune response to group A streptococcal carbohydrate. Finally, the work of Bona and collaborators (2, 27) has shown that the anti-P-2-*6 polyfructosan response can be enhanced by treating adults or neonates with Ab2. They even found one monoclonal Ab2 which mimicked bacterial levan (56) . Those studies indicate that idiotypic manipulations can prime the immune system to respond to polysaccharide antigens. Stein and Soderstrom (65) subsequently showed that protective immunity against Escherichia coli K-13 infection can be obtained by injecting a monoclonal antiidiotypic antibody into newborn mice. This Ab2 was raised against the idiotype of an anticapsular protective antibody. McNamara et al. (42) have observed that adult mice immunized with a monoclonal Ab2 coupled to keyhole limpet hemocyanin are protected against Streptococcus pneumoniae. In that case, Ab2 recognizes a determinant of the major IdX of antiphosphorylcholine antibody.
All the examples cited above demonstrate that idiotypic vaccines can be successfully used to confer protective immunity against viral, parasitic, and bacterial infections and that successful idiotypic priming can be elicited for peptidic as well as for carbohydrate antigens. Nevertheless, the injection of an Ab2 does not always induce or prime for an Ab1 response. In some cases, Ab2 injection actually induces the suppression of the Ab1 response, leading to expression of the corresponding idiotype (for a review, see reference 50). In the case of the infectious-disease models, idiotypic suppression might lead to increased pathogenicity (34) . The mode of Ab2 injection also can influence its outcome: in the arsonate system, treatment with monoclonal Ab2 leads to idiotopic suppression in A/J mice (28), whereas injection of the same monoclonal Ab2 coupled to keyhole limpet hemocyanin in CFA leads to increased idiotopic expression and primes the A/J mice for the Ab1 response (J. Marvel, unpublished observations). This suggests that one must be very careful in designing idiotype vaccines or in using idiotypic manipulation to induce protection against infectious diseases.
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DEVELOPMENT OF IDEAL IDIOTYPIC VACCINES
In the two preceding sections, consideration was given to how the concepts of the idiotypic cascade and of the internal image (Ab2I) can be applied to the development of idiotypic vaccines. Obviously, much more needs to be done before the results obtained with experimental animal models can be applied for use in humans. Nevertheless, such studies have helped to define the criteria which need to be considered in the development of successful vaccines. Most of these criteria have already been reviewed by others (3, 13) . Ideally, an idiotypic vaccine should be able to confer protective immunity. When the original epitope is a peptide, there is clear evidence that Ab2j can mimic the physiological and immunological properties of this epitope and thus fulfill most of the criteria given above. These criteria lead to a conservative definition of the internal image. Indeed, an Ab2P can still function as a surrogate antigen, without presenting the same tertiary structure (see reference 68 for a detailed discussion of this point). Here, immunological efficiency would be the main criterion to define an Ab2A. This is most likely the only way in which the internal image of a carbohydrate antigen can be defined. Potential Ab2p antibodies mimicking carbohydrate antigen have been studied experimentally. In one system, Ab2 immunization induces protective immunity (65); in another, Ab2 immunization activates the production of epitope-binding antibodies in various species (58) . In the polyfructosan system, a monoclonal anti-idiotypic antibody mimicking bacterial levan has been observed (56) (19) .
Another issue of concern with vaccination is the use of adjuvants. The latter have been used in several instances (Table 1) . In some studies no (11, 26, 45, 51) . The use of anti-idiotypes to control autoimmune reactions (72) , enteric intoxication (1) , and the rejection of allograft (40) has also been suggested. VOL. 56, 1988 on August 14, 2017 by guest http://iai.asm.org/
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The possibility of using anti-idiotypic antibody to immunize against human immunodeficiency virus, the causative agent of acquired immunodeficiency syndrome, is currently being explored in several laboratories (74 
